Navigation Links
Fate Therapeutics and Stemgent Launch Catalyst: A Unique Industry Program for First Access to the Most Advanced Induced Pluripotent Stem Cell Technology
Date:4/23/2009

>Stemgent advances stem cell science by providing proprietary reagents and tools developed by some of the world's leading stem cell scientists. Stemgent's product offering has been specifically optimized for and screened against stem cells, and includes small molecules for pluripotency, self-renewal, and differentiation, viral-delivered transcription factors, matrices, cell lines, cytokines, antibodies, transfection reagents, and more. This unique product mix is designed to serve researchers who study stem cell biology and regenerative medicine, and those who use cells derived from stem cells as tools to advance their understanding of major diseases. With dual headquarters in Boston, MA, and San Diego, CA, Stemgent is well positioned to serve these major research markets. For more information, please visit http://www.stemgent.com.

Fate Therapeutics and Stemgent, along with Genzyme, Burrill & Company and WIRED Magazine, will be featured in a panel presentation entitled "Mastering Your (Cell) Fate: Stem Cells, iPSCs and the Future of Medicine" on May 18, 2009 at 2 p.m. at the 2009 BIO International Convention in Atlanta, GA.


'/>"/>
SOURCE Fate Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... , Aug. 3, 2015  Merck KGaA, Darmstadt, ... and top-quality high-tech products in the healthcare, life science ... US-based company Nano-C, their development and launch of promising ... photovoltaics (OPV). Merck KGaA, Darmstadt, Germany ... growing OPV sector. Novel derivatives: highly stable, ...
(Date:8/3/2015)... 2015  Aethlon Medical, Inc. (Nasdaq: AEMD ), ... life-threatening diseases, today announced that it will host its ... on Thursday, August 13, 2015 at 4:30 p.m. Eastern ... the release of fiscal 2016 first quarter results.  A ... two hours after the call at the Investor Relations ...
(Date:8/3/2015)... GERMANTOWN, Md. , Aug. 3, 2015   ... it will release first half and second quarter 2015 ... 10 th , 2015.  The Company will host a ... results and provide a general business update. ... (Domestic US) and 1-412-902-4262 (International), and asking to join ...
(Date:8/3/2015)... - RepliCel Life Sciences Inc. (TSX.V: RP) (OTCQB: REPCF), a ... autologous cell therapies, announced today that RepliCel,s CEO, David ... in Minneapolis, Minnesota on August 5 ... highlight RepliCel,s 18-month milestones including CE Mark for its RCI-02 ... clinical data from both RCT-01 (tendon) and RCS-01 (skin) clinical ...
Breaking Biology Technology:Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 2Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 3Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 4Aethlon Medical To Host First Quarter Fiscal 2016 Investor Call on August 13, 2015 2Intrexon to Announce First Half and Second Quarter 2015 Financial Results and Host Conference Call on August 10th 2RepliCel Presenting at InvestMNT Investor Conference in Minneapolis 2
... 19, 2012  Nautilus Neurosciences announced today that their ... subsidiary of Stellar Pharmaceuticals, was granted a Notice ... CAMBIA® (diclofenac potassium for oral solution) in the ... in adults. CAMBIA® is expected to be launched ...
... Cancer Research Centre (CNIO) routinely runs such tests on samples ... just the first step towards a truly personalised medicine. And ... in each organism at a molecular scale: the genes that ... antibodies circulating through the bloodstream; and the length of the ...
... of yoghurt have a note telling you that the product ... the spatial arrangement of their atoms. The two"isomers", L(+) and ... light to the right or left respectively. Of course the ... is not confined to solutions of yoghurt. Light interacts in ...
Cached Biology Technology:Nautilus Neurosciences, Inc. Announces a New Approval for CAMBIA® for the Acute Treatment of Migraine 2Nautilus Neurosciences, Inc. Announces a New Approval for CAMBIA® for the Acute Treatment of Migraine 3CNIO researchers take part in the most comprehensive personalized medicine study performed to date 2CNIO researchers take part in the most comprehensive personalized medicine study performed to date 3Designer lights from the physics lab 2
(Date:7/21/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... on the growing mobile commerce market and creator ... has filed provisional patent 62/192218 for ... This invention highlights next generation payment technology from ... also the user using unique personal identifiers including ...
(Date:7/9/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), a leading ... will report financial results for the fourth quarter and ... the close of market. The company will host a ... p.m. PT (5:00 p.m. ET), during which management may ... the live call, analysts and investors should dial 888-455-2260 ...
(Date:7/8/2015)... YORK , July 8, 2015  BD (Becton, ... BD & Guidepoint Mentor, a new program ... Guidepoint,s expert network services. BD is ... to improve healthcare delivery and outcomes and, with the ... entrepreneur will be able to directly engage with industry ...
Breaking Biology News(10 mins):NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3
... malaria parasites form mutations that make them stubbornly resistant ... new treatments for a disease that afflicts more than ... disease models using yeast and successfully introduced five mutations ... The study, featured as the cover story of the ...
... consequences for humans and most animals but not Australia's ... The University of Queensland has found that unlike most ... starvation, the green-striped burrowing frog is able to absorb ... food, than frogs that had eaten regularly. , "They ...
... community over the evolution of the Great White shark, and ... Wright State University Lake Campus, is right in the middle ... one of the most feared predators of the sea, evolved ... rests with the mako shark. , "Most scientists would probably ...
Cached Biology News:Molecular models advance the fight against malaria 2A frog's life is food for thought 2A frog's life is food for thought 3Great White shark evolution debate involves WSU Lake Campus geology professor 2
Agarose, Biotechnology grade, 500g...
AM100 is an aqueous-based, permanent mounting media designed for use with alkaline phosphatase and immunoperoxidase stained tissue sections....
... The c-Jun proto-oncogene was first identified as ... v-jun oncogene. Jun B and Jun D have ... in their C-terminal regions, which are involved in ... which are involved in transcriptional activation, diverge. ...
...
Biology Products: